TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Investor Securities Class Action Lawsuit 05/31/2016

  • If you purchased shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Eagle Pharmaceuticals Inc
Security
NASDAQ: EGRX

Case Name
Eagle Pharmaceuticals Shareholder Class Action Lawsuit 05/31/2016
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the District of New Jersey

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Eagle Pharmaceuticals Inc.
Summary

August 3, 2017- The court granted defendants' motion to dismiss.
December 16, 2016 - A motion to dismiss the amended complaint was filed.

October 31, 2016 - An amended complaint was filed.

May 31, 2016 - An investor in shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Eagle Pharmaceuticals Inc in connection with certain allegedly false and misleading statements made between February 23, 2016 and March 18, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) common shares between February 23, 2016 and March 18, 2016, that the defendants violated Federal Securities Laws.

Shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) reached as high as $97.17 per share in December 2015.

On February 25, 2016, Eagle Pharmaceuticals Inc reported its fourth quarter and full year 2015 results. Eagle Pharmaceuticals Inc reported that its Total Revenue rose from $19.10 million for the 12 months period that ended on September 30, 2014 to $66.23 million for the 12 months period that ended on December 31, 2015 and that its Net Loss of $17.98 million for the 12 months period that ended on September 30, 2014 turned into a Net Income of $2.57 million for the 12 months period that ended on December 31, 2015.

On February 25, 2016, Eagle Pharmaceuticals Inc's CEO stated, regarding the pending New Drug Application ( NDA ) for the Company's anticoagulant drug KANGIO™, We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.

Then, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA cannot approve the application in its present form and requested additional information regarding the substances used in KANGIO™.

Shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) declined to as low as $35.10 per share on March 28, 2016.